Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Solenis-Diversey deal highlights trend for strategic, sustainability-focused acquisitions

By Brian Buntz | July 5, 2023

SolenisSolenis, a specialty chemicals company serving water-intensive industries, wrapped up its $4.6 billion acquisition of Diversey Holdings, Ltd., a supplier of hygiene, infection prevention, and cleaning products to global pharmaceutical companies.

This acquisition comes amid a trend of smaller, more strategic M&A activity in the pharma sector during the second quarter of 2023. While the Solenis-Diversey deal bucks this trend in terms of deal size, it aligns with the strategic nature of recent acquisitions in the industry.

The merger creates a global firm specializing in integrated water and hygiene that operates in more than 130 countries with 71 sites and 15,000 employees. 

Before the acquisition, Solenis already served a diverse number of industrial sectors, including pulp, paper, oil and gas, chemical processing, mining, biorefining, power and municipal markets. 

Solenis-Diversey deal could be harbinger of more chemicals sector M&A deals

The acquisition aligns with a broader trend in the chemicals sector. Despite experiencing a surge in M&A activity in 2021, the sector saw a 21% drop in mergers and acquisitions in 2022, according to Deloitte. This downturn followed a high of 158 deals in the first quarter, marking a decrease from a 10-year peak in 2021. However, the future appears optimistic. Deloitte reported that 90% of chemical executives anticipate pursuing M&A in 2023. This demonstrates resilience and strategic focus amid global economic challenges.

Driving factors

The deal aligns with several factors driving M&A in the chemicals sector, including attractive valuations, abundant access to capital and the pursuit of strategic acquisitions to build market presence and competitiveness. 

Sustainability considerations

Notably, the Solenis-Diversey deal underscores the pursuit of sustainable technologies, a driver in the chemicals sector’s M&A market. With an emphasis on water and hygiene solutions, this merger reflects the increasing importance of sustainability and operational efficiency within the chemicals and pharmaceutical industries.

Looking ahead

PwC projects that the chemicals M&A market will maintain its momentum in the second half of 2023. Factors that could drive the trend include continued demand for transformative deals, cross-border collaborations and the pursuit of sustainable technologies to address environmental challenges.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].

Tell Us What You Think! Cancel reply

Related Articles Read More >

From automation islands to connected plants: A roadmap for pharma manufacturers
This is the logo of Johnson & Johnson.
Johnson & Johnson announces new North Carolina pharma plant
Myths about conveyors and measures to make data-driven purchasing decisions
The blueprint for personalized biopharma
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE